Meclizine (antivert) manufacturing plant cost?

I can help, but I need to clarify what you mean by “manufacturing plant cost,” because the number depends a lot on the scope and regulatory path. Also, I can’t provide precise pricing for a specific site without details, but I can give realistic cost ranges and the key drivers.

Typical ranges (very rough, but useful)

1) Generic oral solid (tablet/capsule) plant

• Scale: small–mid capacity (e.g., hundreds of millions of tablets/year possible, depending on line count)
• Total capex (equipment + facility build-out): ~$10M to $50M
• If you need higher automation, multiple product lines, larger utilities, and higher containment/QC: ~$50M to $150M

2) Liquid (syrup) or other dosage forms

• Often adds complexity for heating/cooling, viscosity control, filling systems, and stability
• Total capex: typically ~$15M to $80M (can be higher)

3) API (meclizine active ingredient) vs. finished-dose manufacturing

This is the biggest lever.

• Finished-dose (formulation + tableting/filling): cost ranges above
• API manufacturing (chemical synthesis, reactors, solvent recovery, controls):
  • ~$30M to $200M+ depending on synthesis route, containment, EHS, and compliance level

Key factors that drive cost

• Dosage form: tablets vs liquids vs injectables
• Capacity target: small pilot vs large commercial scale
• API integration: buying API vs making API in-house
• Regulatory target: US FDA (cGMP), EU (EudraGMP), WHO, etc.
• Quality/QC requirements: additional testing labs, stability chambers, analytical equipment (HPLC/GC, dissolution, etc.)
• Site utilities & EHS: HVAC/cleanroom class, HVAC redundancy, waste treatment, solvent recovery
• Number of SKUs and changeover frequency
• Cleanroom level: many solid oral sites are not extreme cleanrooms, but QC/packaging areas often require controlled environments

“Plant cost” also depends on what stage you mean

• Greenfield build (new site): higher capex
• Brownfield expansion (repurpose existing facility): often cheaper (sometimes significantly)
• Contract manufacturing (CDMO) instead of building: can avoid most capex

Quick questions so I can narrow it down

1. Do you mean finished-dose tablets/capsules only, or API too?
2. What target market: US FDA / EU / other?
3. Estimated scale: units per year (or batches per year)?
4. Are you considering building from scratch or using an existing facility/CDMO?

Reply with those, and I’ll give you a tighter cost range and a rough breakdown (facility, cleanroom, equipment, QC lab, utilities, validation/commissioning, and working capital).